{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:39:18Z","timestamp":1793839158459,"version":"4.6.1"},"reference-count":44,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objectives: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn\u2019s disease, is characterized by chronic gut inflammation driven by microbial dysbiosis and immune dysfunction. Current therapies primarily involve anti-inflammatory and immunomodulatory strategies; however, many patients experience an inadequate response or a gradual loss of efficacy over time. This study evaluates the clinical efficacy of personalized microbiome modulation (PMM)\u2014an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates. Methods: This was a single-arm, open-label validation trial involving 27 patients with moderate-to-severe IBD who had experienced prior treatment failure. Participants underwent three months of PMM, which included personalized dietary modifications, targeted probiotic supplementation, and antimicrobial interventions based on gut microbiome sequencing. Primary outcomes included stool frequency and consistency as well as inflammatory markers (C-reactive protein and fecal calprotectin), while secondary outcomes assessed nutritional status, metabolic function, and quality of life. Statistical analyses included paired t-tests and repeated measures ANOVA to determine significant changes over time. Results: PMM led to significant clinical improvements, including a 58% reduction in stool frequency (p &lt; 0.001) and improved stool consistency. CRP and fecal calprotectin levels decreased markedly (p &lt; 0.001), suggesting reduced systemic inflammation. Additionally, iron, vitamin B12, and vitamin D deficiencies improved (p &lt; 0.001), alongside weight gain and increased energy levels. Notably, patients on anti-TNF biologics showed enhanced response rates, suggesting potential synergistic effects between microbiome modulation and biologic therapy. Conclusions: This study highlights PMM as a promising adjunctive therapy for IBD, demonstrating benefits across clinical, inflammatory, and metabolic parameters. While findings support the role of microbiome-targeted interventions in disease management, larger randomized controlled trials are required to confirm the long-term efficacy and applicability in broader patient populations.<\/jats:p>","DOI":"10.3390\/biomedicines13040795","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:01:00Z","timestamp":1743073260000},"page":"795","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Introducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease: Results from NostraBiome\u2019s Internal Validation Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Adrian","family":"Goldi\u0219","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-9160","authenticated-orcid":false,"given":"Radu","family":"Dragomir","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-1208","authenticated-orcid":false,"given":"Marina Adriana","family":"Mercioni","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"},{"name":"Applied Electronics Department, Faculty of Electronics, Telecommunications and Information Technologies, Politehnica University Timi\u0219oara, 300223 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Goldi\u0219","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Sirca","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Enatescu","sequence":"additional","affiliation":[{"name":"Twelfth Department, Neonatology Clinic, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Belei","sequence":"additional","affiliation":[{"name":"First Pediatric Clinic, Disturbances of Growth and Development on Children Research Center, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"},{"name":"First Pediatric Clinic, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2021","journal-title":"Lancet"},{"key":"ref_2","first-page":"537","article-title":"Therapeutic escape in IBD: Switching, optimizing, and combining therapies","volume":"19","author":"Allez","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2019.11.003","article-title":"The microbiome and inflammatory bowel disease","volume":"145","author":"Glassner","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/gutjnl-2016-313235","article-title":"A microbial signature for Crohn\u2019s disease","volume":"66","author":"Pascal","year":"2017","journal-title":"Gut"},{"key":"ref_5","first-page":"5672","article-title":"Gut microbiota offers clues to the pathogenesis of inflammatory bowel disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Arze","year":"2019","journal-title":"Nature"},{"key":"ref_7","first-page":"2844","article-title":"Therapeutic opportunities in inflammatory bowel disease: Mechanistic dissection of host-microbiome interactions","volume":"185","author":"Plichta","year":"2022","journal-title":"Cell"},{"key":"ref_8","first-page":"312","article-title":"AI-driven microbiome-based diagnostics and therapeutics in inflammatory bowel disease","volume":"8","author":"Zhang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_9","first-page":"302","article-title":"Urbanization and the gut microbiota in IBD","volume":"19","author":"Zuo","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","unstructured":"Holleran, G., Lopetuso, L.R., Petito, V., Graziani, C., Ianiro, G., and McNamara, D. (2020). The role of fecal calprotectin in monitoring acute severe ulcerative colitis. Front. Med., 7."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11122","DOI":"10.12998\/wjcc.v9.i36.11122","article-title":"Diet and microbiome in the beginning of the sequence of gut inflammation","volume":"9","author":"Ceballos","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_12","first-page":"1776","article-title":"Crohn\u2019s disease","volume":"401","author":"Torres","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (IBD) consensus initiative","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2040622319838443","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/flgastro-2014-100514","article-title":"A UK cost of care model for inflammatory bowel disease","volume":"6","author":"Ghosh","year":"2015","journal-title":"Frontline Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bpg.2006.03.001","article-title":"Nutrition in inflammatory bowel disease","volume":"20","year":"2006","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.gastro.2019.11.294","article-title":"Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review","volume":"158","author":"Pittayanon","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zuo, T., and Ng, S.C. (2018). The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02247"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41579-019-0213-6","article-title":"Microbial genes and pathways in inflammatory bowel disease","volume":"17","author":"Schirmer","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Parada Venegas, D., De la Fuente, M.K., Landskron, G., Gonz\u00e1lez, M.J., Quera, R., Dijkstra, G., Harmsen, H.J.M., Faber, K.N., and Hermoso, M.A. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00277"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Sayin","year":"2016","journal-title":"Cell Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus","volume":"112","author":"Rezaie","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1038\/s41467-018-05470-4","article-title":"Microbial tryptophan catabolites in health and disease","volume":"9","author":"Roager","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/ibd.21590","article-title":"Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn\u2019s disease","volume":"17","author":"Ng","year":"2011","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of inflammation in inflammatory bowel disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short-chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune system","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.immuni.2017.04.008","article-title":"Homeostatic immunity and the microbiota","volume":"46","author":"Belkaid","year":"2017","journal-title":"Immunity"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/MCO.0000000000000226","article-title":"Micronutrient deficiencies in inflammatory bowel disease","volume":"18","author":"Weisshof","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_37","first-page":"2101","article-title":"Pathogenesis and treatment of anemia in inflammatory bowel disease","volume":"138","author":"Weiss","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000243791","article-title":"The role of hepcidin in iron metabolism","volume":"122","author":"Nemeth","year":"2009","journal-title":"Acta Haematol."},{"key":"ref_39","first-page":"604","article-title":"Vitamin B12 deficiency in inflammatory bowel disease: Prevalence and mechanisms","volume":"17","author":"Oustamanolakis","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_40","first-page":"9","article-title":"Vitamin B12\u2013function and deficiency","volume":"6","author":"Biesalski","year":"2013","journal-title":"Gastroenterol. Hepatol. Bed Bench."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.gtc.2017.09.007","article-title":"Nutritional interventions in the patient with inflammatory bowel disease","volume":"47","author":"Limketkai","year":"2018","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2019.07.025","article-title":"Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases","volume":"157","author":"Aden","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1900996","article-title":"Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn\u2019s disease","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Microbes."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/4\/795\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:00:22Z","timestamp":1760029222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/4\/795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["biomedicines13040795"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13040795","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}